Results 41 to 50 of about 212,694 (168)

Assessing cardiovascular benefits of intensive blood pressure lowering in high‐risk undiagnosed HFpEF patients

ESC Heart Failure
Aims Heart failure with preserved ejection fraction (HFpEF) is often underdiagnosed. This study evaluates the HFpEF‐ABA score's ability to identify high‐risk, undiagnosed HFpEF subgroups with elevated cardiovascular event rates and assesses the impact of
Xinru Liu, Zhiyan Wang, Chang Hua, Yanfang Wu, Yangyang Tang, Yuling Xiong, Jingwei Liu, Jiaqi Zhang, Qiang Lv, Chao Jiang, Jianzeng Dong, Xin Du   +11 more
doaj   +1 more source

Predictive value of estimated plasma volume for postoperative hypotension in percutaneous intramyocardial septal radiofrequency ablation treating for hypertrophic obstructive cardiomyopathy

BMC Cardiovascular Disorders
Background Estimated plasma volume status (ePVS) estimated by the Duarte formula is associated with clinical outcomes in patients with heart failure.
Bo Shan, Jing Li, Zhangwei Shi, Chao Han, Juan Zhang, Jia Zhao, Rui Hu, Liwen Liu, Shengjun Ta   +8 more
doaj   +1 more source

Echocardiography-guided percutaneous intramyocardial alginate hydrogel implants for heart failure: canine models with 6-month outcomes

Frontiers in Cardiovascular Medicine
BackgroundEchocardiography-guided percutaneous intramyocardial alginate-hydrogel implantation (PIMAHI) is a novel treatment approach for heart failure (HF).
Hui Ma, Wenqing Gong, D. Scott Lim, Jing Li, Shengjun Ta, Rui Hu, Xiaojuan Li, Minjuan Zheng, Liwen Liu   +8 more
doaj   +1 more source

Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID‐19 Pandemic

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Dedicated hypertrophic cardiomyopathy (HCM) center cohorts have reported reductions in HCM‐related deaths, likely due to the introduction of contemporary treatments.
Ahmed Sayed, Barry J. Maron, Ethan J. Rowin, Martin S. Maron   +3 more
doaj   +1 more source

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy previously treated with advanced therapies are not established.
Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Woon Y. Wu, Maria C. Reuter, Yuhe Xia, Isabel C. Alvarez, Mark V. Sherrid   +7 more
doaj   +1 more source

Hypocalcemic cardiomyopathy

Revista Portuguesa de Cardiologia (English Edition), 2013
The association between hypocalcemia and heart failure is rare. There are few reported cases in the literature of this association, which is termed hypocalcemic cardiomyopathy. We report the case of a 61-year-old woman with no relevant medical history, admitted for progressively worsening exertional dyspnea, orthopnea and edema of the lower limbs for a
Patrício, Aguiar, Diogo, Cruz, Rita, Ferro Rodrigues, Lígia, Peixoto, Francisco, Araújo, José Luís, Ducla Soares   +5 more
openaire   +2 more sources

Explainable artificial intelligence identifies and localizes left ventricular scar in hypertrophic cardiomyopathy using 12-Lead electrocardiogram

Scientific Reports
Left ventricular (LV) scar is a major risk factor for sudden death and heart failure in hypertrophic cardiomyopathy (HCM). LV scar evolves over time and needs longitudinal assessment. Currently, LV scar detection relies on late gadolinium enhancement MRI,
Kasra Nezamabadi, Sanjay Sivalokanathan, Jiwon Lee, Talha Tanriverdi, Meiling Chen, Daiyin Lu, Jadyn Abraham, Neda Sardaripour, Pengyuan Li, Parvin Mousavi, M. Roselle Abraham   +10 more
doaj   +1 more source

The cardiomyopathies [PDF]

Heart, 1994
W J, McKenna, A C, Beiras, M P, Lado
openaire   +2 more sources

Advancements and Applications of Artificial Intelligence in Hypertrophic Cardiomyopathy: A Comprehensive Review

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is a common cardiovascular disease and one of the leading causes of exercise-induced sudden cardiac death in adolescents.
Huanhuan Ma, Jing Li, Shengjun Ta, Liang Yu, Fangqi Ruan, Liwen Liu   +5 more
doaj   +1 more source

Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis

Journal of Nanobiotechnology
Background Cardiac fibrosis plays a critical role in the progression of various forms of heart disease, significantly increasing the risk of sudden cardiac death.
Xueli Zhao, Yuze Qin, Bowen Li, Yue Wang, Jiao Liu, Bo Wang, Jia Zhao, Jiaqi Yin, Lanlan Zhang, Jing Li, Junzhe Huang, Kun Chen, Liwen Liu, Yuanming Wu   +13 more
doaj   +1 more source